tdi01
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 2, 2023 (NCT06102083)
Timeline
Indications
Mechanism of action
- Rho-associated protein kinase 2INHIBITOR
ROCK2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06169722 | Phase 1/Phase 2 (Phase 2) | Jan 31, 2024 | Beijing Tide Pharmaceutical Co., Ltd |
| NCT06102083 | Phase 2 | Nov 2, 2023 | Beijing Tide Pharmaceutical Co., Ltd |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Beijing Tide Pharmaceutical Co., Ltd | For profit | 2 | 2 | 1 | 2023 |
1 organizations
Page 1 / 1